Phase 2 Head and Neck Cancer Trial, Recruiting NCT07497607 Sponsor: Sara Medek Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT07497607
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with squamous cell carcinoma of the oropharynx (a type of throat cancer) confirmed by a tissue or cell sample, and who are planned to receive chemotherapy combined with radiation as their main treatment
  • People whose throat cancer has tested positive for a protein called p16, confirmed through laboratory testing of a tissue sample
  • People whose cancer is at a specific stage — either spread to nearby lymph nodes (certain stage combinations) or a larger tumour without lymph node involvement — as classified by a standard cancer staging system (confirm with trial site)
  • People who have had a PET/CT scan showing measurable cancer, taken within approximately 45 days before eligibility is confirmed
  • People aged 18 or older
  • People who are in a reasonable general state of health, able to carry out daily activities with at most some limitations (confirm with trial site)
  • People whose treating doctor considers them suitable to receive a standard chemotherapy drug called cisplatin
  • People who agree to use effective contraception throughout the study (applies to women who could become pregnant and to men)
  • People who are willing and able to read and sign a written consent form

Who may not be able to join:

  • People whose cancer has spread to other parts of the body or has come back after previous treatment
  • People whose cancer has been found in a neck lymph node but where the original site of the cancer cannot be identified
  • People who have previously had radiation therapy in an area that would overlap with the radiation fields planned for this trial
  • People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the study
  • People who have an active autoimmune or connective tissue disease that requires ongoing systemic treatment, in the opinion of the treating doctor
  • People who are currently taking part in another clinical trial involving an experimental treatment
  • People who have any other serious uncontrolled medical condition that the treating doctor believes would make participation unsafe or unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 513-584-7698

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sara Medek
Registry
ClinicalTrials.gov
Start date
13 May 2026
Est. completion
13 May 2031

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in dose and volume to all clinical target volumes (CTV) via Progression-Free Survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov